NucMed > PET > PET tumor imaging > Thyroid Cancer

Thyroid Cancer:

General:

I-131 scanning has been the mainstay for the evaluation of recurrent thyroid carcinoma. Patients who are found to have I-131 accumulating local recurrences or metastases on diagnostic scans will usually receive subsequent therapeutic I-131 doses which may be curative. Unfortunately, not all recurrences are iodine avid (50-60% of papillary and 64-67% of follicular cancer recurrences are iodine avid [4]). Patients with elevated human thyroglobulin levels, but negative I-131 scans pose a diagnostic and therapeutic dilemma. Although therapy with I-131 has been performed in these patients with subsequent decline in thyroglobulin levels [5], one can never be certain if all sites of disease have been adequately treated. Surgical resection of untreated sites of disease would certainly be desirable [4]. Other agents such as Tc-sestamibi, Tc-tetrofosmin, and thallium-201 have all be used to evaluate for non-iodine avid recurrent cancer and metastatic disease. Although useful for locoregional disease, physiologic accumulation of these agents in other organs (particularly within the abdomen) limits their usefulness for whole body examinations. FDG PET imaging has also shown great promise in the detection of metastatic disease in post-thyroidectomy/I-131 ablation patients [1,2]. Unlike conventional imaging, FDG PET imaging can detect metastatic disease to normal sized lymph nodes [1]. I-131 scintigraphy and FDG PET imaging are complementary diagnostic methods for the evaluation of recurrent or metastatic thyroid cancer [3,6]. The iodine uptake of a tumor is inversely related to its glucose metabolism [3]. Tumor uptake is also related to the degree of tumor differentiation [4]. In general, highly differentiated thyroid carcinoma will be I-131 positive and FDG PET negative, while less differentiated cancers will show the reverse (i.e.: FDG PET positive and I-131 negative) [1,6]. It is important to remember that although FDG-positive recurrences may indicate dedifferentiated and more aggressive tumors, this finding does not automatically predict a worse prognosis [4]. Interestingly, patients with higher thyroglobulin levels (above 100 ug/L) have been shown to have a higher incidence of true-positive FDG PET exams [4]. Another benefit of FDG PET imaging is the identification of unsuspected secondary malignancies [4].

One of the benefits of FDG PET imaging is that patients do not need to discontinue hormonal replacement therapy prior to imaging, however, lesion detection can be improved when performing the exam during TSH stimulation (following exogenous thyroid hormone removal) [3] or following rhTSH stimulation [12].

I-124 is a positron emitting agent which may hold promise for imaging differentiated thyroid cancer.

Applications for FDG PET in thyroid cancer:

Diagnosis:

FDG PET is probably not indicated for the diagnosis of thyroid cancer. Not all malignant thyroid lesions will accumulate FDG and some benign lesions will show increased metabolic activity.

Staging:

No information is currently available regarding the utility of FDG PET for the staging of thyroid carcinoma. It will likely not play a primary role.

FDG PET Imaging in Patients with Suspected Recurrent Thyroid Cancer and Negative I-131 Scans:

For the detection of recurrent thyroid cancer in patients with negative I-131 scans, FDG PET imaging has a reported sensitivity of 69-94%, and specificity of 42-95% [1,4,7]. FDG PET can detect the presence of metastatic disease in up to 70% normal sized lymph nodes [7]. Metastases to nodes as small as 4 mm have been demonstrated on PET imaging [7]. FDG PET imaging can have significant impact on patient management in this difficult subset of patients. Treatment can be changed in over 50% of patients based upon FDG PET imaging results [4,8]. A drawback of FDG PET imaging is that diffuse small lung metastases may not be identified and false negative exams can occur even in the presence of nodal metastases [7]. FDG PET imaging should be viewed as another tool for assisting in the detection of non-iodine avid thyroid metastases.

Since detection of sites of disease can be obscured by muscular uptake in the neck, it is important that muscle relaxants be used prior to scanning patients for recurrent thyroid cancer if possible [11].

Recurrent thyroid carcinoma: The patient shown below had a history of thyroid cancer and presented with an elevated thyroglobulin level. After a negative diagnostic scan the patient received 125 mCi of I-131 and a post-therapy whole body iodine exam was performed which demonstrated some tracer uptake in the region of the thyroid bed and faint liver activity (right image below). FDG PET imaging demonstrated widespread pulmonary metastases and pathologic adenopathy in the lower left neck (black arrow). Click here to view rotating PET image (1.2MB)

 

Case1 I131 Case1 Pet

 

Recurrent thyroid carcinoma and a negative PET scan: The patient shown below had a history of thyroid cancer and presented with an elevated thyroglobulin level. On a diagnostic CT scan, the patient was found to have a cystic lesion in the right upper neck containing a central calcification. A whole body I-131 scan was negative and a subsequent PET scan was performed. The PET scan demonstrated no tracer uptake within the patients cystic right neck mass. At surgery, the lesion was found to be metastatic thyroid cancer. It is likely that due to the cystic nature of the lesion the PET scan did not demonstrate significant tracer uptake.

Case2 Ct Case2 Pet

In Hurthle cell carcinoma:

Hurthle cell cancer of the thyroid is a follicular variant composed mostly of oxyphilic follicular cells [11]. Hurthle cell is more aggressive than follicular thyroid cancer and has an overall worse prognosis [11]. FDG accumulation is generally very intense in patients with Hurthle cell cancer and can reveal disease not detected by other imaging methods in about 50% of cases [11].

Recurrent Hurthle cell carcinoma: The patient had a history of Hurthle cell carcinoma of the thyroid. Pulmonary metastases are significantly more evident on the coincidence FDG PET examination (below left black arrows) when compared to the I131 scan (below right blue arrows). A CT scan confirmed the presence of pulmonary metastases (below). Note that a subtle bone metastasis to the high left parietal bone can be seen on I131 images. The FDG PET exam did not include this region.

Hurthle_PET.JPG (17670 bytes)Hurthle_I131.JPG (25235 bytes)

Hurthle_CT.JPG (22135 bytes)

Prognosis:

FDG imaging carries prognostic significance in patients with recurrent thyroid cancer and is an independent predictor of survival [10]. Three year survival is significantly reduced in patients with positive FDG scans (60% survival) when compared woth patients with negative exams (98% survival) [10].

Non-pathologic findings:

Following thyroidectomy, FDG uptake in the thyroid bed is a common finding and does not necessarily indicate recurrent disease unless a definite mass can be identified with other imaging modalities [2]. False positive cases have occurred in association with mediastinal tuberculous adenitis.

Medullary thyroid cancer:

Medullary thyroid cancer (MTC) is a relatively rare disease- composing only 3-10% of all malignant thyroid cancers [9]. Familial forms account for about 25% of cases (MTC is associated with multiple endocrine neoplasia tyoes 2A and 2B) [9]. Metastases to locoregional lymph nodes is common and can be seen in 71-80% of cases at presentation [9]. Distant metastases can be found in about 20% of patients [9]. No single conventional imaging test or nuclear imaging agent has been shown to be very sensitive for the detection of metastatic MTC [9].

Following surgical treatment, elevation of serum calcitonin and CEA levels suggest persistent or recurrent disease [9]. In these patients FDG PET imaging can identify more than twice as many sites of disease than conventional imaging modalities (CT and MR) [9]. FDG PET imaging is less sensitive for the detection of pulmonary and hepatic metastases compared to CT and MR, respectively [9].

REFERENCES:

(1) J Nucl Med 1999; Chung JK, et al. Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole body scan. 40: 986-992

(2) J Nucl Med 2000; Alnafisi NS, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. 41: 1010-1015

(3) J Nucl Med 2000; Moog F, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. 41: 1989-1995

(4) J Nucl Med 2001; Schluter B, et al. Impact of FDG PET on patientw with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan. 42: 71-76

(5) Thyroid 1994; Clark OH, et al. Managament of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. 4 (4): 501-505

(6) J Nucl Med 2001; Shiga T, et al. Comparison of 18F-FDG, 131I-Na, and 201-Tl in diagnosis of recurrent or metastatic thyroid cancer. 42: 414-419

(7) Head Neck 2001; Yeo JS, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for i-131 scan-negative thryoid carcinoma patients with local recurrence in cervical lymph nodes. 23: 94-103

(8) J Nucl Med 2001; Helal BO, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. 42: 1464-1469

(9) J Nucl Med 2002; Szakall S, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. 43: 66-71

(10) Endocrinol Metab Clin North Am 2001; Haugen BR, Lin EC. Isotope imaging for metastaic thyroid cancer. 30: 469-492

(11) J Nucl Med 2003; Lowe VJ, et al. 18F-FDG-PET of patients with Hurthle cell carcinoma. 44: 1402-1406

(12) Eur J Nucl  Med Mol Imaging 2002; Petrich T, et al. Influence of rhTSH on [(18)F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. 29: 641-647

Page 1 of 69
Next Page